Welcome to Publication page of CPPsite 2.0

This page provides the information about research articles and patents from which the entries have been made in CPPsite 2.0

1. A Heparan Sulfate-Binding Cell Penetrating Peptide for Tumor Targeting and Migration Inhibition.
2. Efficient Cargo Delivery into Adult Brain Tissue Using Short Cell-Penetrating Peptides.
3. Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular drug delivery.
4. Macrocyclic cell penetrating peptides: a study of structure-penetration properties.
5. Uptake and cellular distribution of nucleolar targeting peptides (NrTPs) in different cell types.
6. Cell penetrating peptide mediated quantum dot delivery and release in live mammalian cells.
7. Identification of a novel cell-penetrating peptide targeting human glioblastoma cell lines as a cancer-homing transporter.
8. Dual peptide conjugation strategy for improved cellular uptake and mitochondria targeting.
9. Efficient and High-Speed Transduction of an Antibody into Living Cells Using a Multifunctional Nanocarrier System to Control Intracellular Trafficking.
10. Attachment of cell-binding ligands to arginine-rich cell-penetrating peptides enables cytosolic translocation of complexed siRNA.
11. Peptide internalization enabled by folding: triple helical cell-penetrating peptides.
12. Covalent attachment of cyclic TAT peptides to GFP results in protein delivery into live cells with immediate bioavailability.
13. Marine antimicrobial peptide tachyplesin as an efficient nanocarrier for macromolecule delivery in plant and mammalian cells.
14. Protein and siRNA delivery by transportan and transportan 10 into colorectal cancer cell lines.
15. Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer.
16. Exogenous c-Myc Blocks Differentiation and Improves Expansion of Human Erythroblasts In vitro.
17. Aib-containing peptide analogs: cellular uptake and utilization in oligonucleotide delivery.
18. Cell penetrating peptides as efficient nanocarriers for delivery of antifungal compound, natamycin for the treatment of fungal keratitis.
19. Design, synthesis and biological evaluation of novel peptides with anti-cancer and drug resistance-reversing activities.
20. Identification and characterization of novel protein-derived arginine-rich cell-penetrating peptides.
21. Tumor-targeted paclitaxel delivery and enhanced penetration using TAT-decorated liposomes comprising redox-responsive poly(ethylene glycol).
22. Tumor homing cell penetrating peptide decorated nanoparticles used for enhancing tumor targeting delivery and therapy.
23. Secondary conformational conversion is involved in glycosaminoglycans-mediated cellular uptake of the cationic cell-penetrating peptide PACAP.
24. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.
25. The role of tryptophans on the cellular uptake and membrane interaction of arginine-rich cell penetrating peptides.
26. Antisense growth inhibition of methicillin-resistant Staphylococcus aureus by locked nucleic acid conjugated with cell-penetrating peptide as a novel FtsZ inhibitor.
27. A general strategy for developing cell-permeable photo-modulatable organic fluorescent probes for live-cell super-resolution imaging.
28. The discovery of Hsp70 domain with cell-penetrating activity.
29. Enhanced cellular uptake of albumin-based lyophilisomes when functionalized with cell-penetrating peptide TAT in HeLa cells.
30. Controlled delivery of BID protein fused with TAT peptide sensitizes cancer cells to apoptosis.
31. Peptide-micelle hybrids containing fasudil for targeted delivery to the pulmonary arteries and arterioles to treat pulmonary arterial hypertension.
32. Peptide-bridged dinuclear Ru(II) complex for mitochondrial targeted monitoring of dynamic changes to oxygen concentration and ROS generation in live mammalian cells.
33. X-pep, a novel cell-penetrating peptide motif derived from the hepatitis B virus.
34. The improved blood-brain barrier permeability of endomorphin-1 using the cell-penetrating peptide synB3 with three different linkages.
35. Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy.
36. Cell-penetrating peptide delivery of biologically active oct4 protein into cultured Takifugu rubripes spermary cells.
37. Rational modification of oligoarginine for highly efficient siRNA delivery: structure-activity relationship and mechanism of intracellular trafficking of siRNA.
38. Cell-penetrating helical peptides having l-arginines and five-membered ring α,α-disubstituted α-amino acids.
39. Activatable cell penetrating peptide-peptide nucleic acid conjugate via reduction of azobenzene PEG chains.
40. Preparation of TAT peptide-modified poly(N-isopropylacrylamide) microgel particles and their cellular uptake, intracellular distribution, and influence on cytoviability in response to temperature change.
41. Antibacterial activities of amphiphilic cyclic cell-penetrating peptides against multidrug-resistant pathogens.
42. Enhanced intracellular translocation and biodistribution of gold nanoparticles functionalized with a cell-penetrating peptide (VG-21) from vesicular stomatitis virus.
43. Effects of cargo molecules on membrane perturbation caused by transportan10 based cell-penetrating peptides.
44. Massive glycosaminoglycan-dependent entry of Trp-containing cell-penetrating peptides induced by exogenous sphingomyelinase or cholesterol depletion.
45. Distal phenylalanine modification for enhancing cellular delivery of fluorophores, proteins and quantum dots by cell penetrating peptides.
46. Second generation, arginine-rich (R-X'-R)(4)-type cell-penetrating α-ω-α-peptides with constrained, chiral ω-amino acids (X') for enhanced cargo delivery into cells.
47. Systemic delivery of P42 peptide: a new weapon to fight Huntington's disease.
48. Novel peptide VIP-TAT with higher affinity for PAC1 inhibited scopolamine induced amnesia.
49. Cell-penetrating, dimeric α-helical peptides: nanomolar inhibitors of HIV-1 transcription.
50. Translocation of cell-penetrating peptides across the plasma membrane is controlled by cholesterol and microenvironment created by membranous proteins.
51. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.
52. The targeted transduction of MMP-overexpressing tumor cells by ACPP-HPMA copolymer-coated adenovirus conjugates.
53. Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery.
54. A targeted ultrasound contrast agent carrying gene and cell-penetrating peptide: preparation and gene transfection in vitro.
55. Structural parameters modulating the cellular uptake of disulfide-rich cyclic cell-penetrating peptides: MCoTI-II and SFTI-1.
56. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin.
57. Arginine-rich, cell penetrating peptide-anti-microRNA complexes decrease glioblastoma migration potential.
58. Design and evaluation of solid lipid nanoparticles modified with peptide ligand for oral delivery of protein drugs.
59. Functional properties of a novel hybrid antimicrobial peptide NS: potent antitumor activity and efficient plasmid delivery.
60. Structure analysis and conformational transitions of the cell penetrating peptide transportan 10 in the membrane-bound state.
61. Protein delivery into live cells by incubation with an endosomolytic agent.
62. A novel cell-penetrating peptide to facilitate intercellular transport of fused proteins.
63. Local gene silencing in plants via synthetic dsRNA and carrier peptide.
64. The design and delivery of a PKA inhibitory polypeptide to treat SCA1.
65. Octaarginine-modified liposomes enhance cross-presentation by promoting the C-terminal trimming of antigen peptide.
66. Early endosomal escape of a cyclic cell-penetrating peptide allows effective cytosolic cargo delivery.
67. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals.
68. Controlled release of free doxorubicin from peptide-drug conjugates by drug loading.
69. A cell-penetrating antibody fragment against HIV-1 Rev has high antiviral activity: characterization of the paratope.
70. Designed cell penetrating peptide dendrimers efficiently internalize cargo into cells.
71. Interaction of amphiphilic α-helical cell-penetrating peptides with heparan sulfate.
72. Elastin-like polypeptides: the influence of its molecular weight on local hyperthermia-induced tumor accumulation.
73. Simultaneous imaging and restoration of cell function using cell permeable peptide probe.
74. Contrasting effects of cysteine modification on the transfection efficiency of amphipathic peptides.
75. The tetrapeptide core of the carrier peptide Xentry is cell-penetrating: novel activatable forms of Xentry.
76. HIV-TAT enhances the transdermal delivery of NSAID drugs from liquid crystalline mesophases.
77. A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth.
78. Highly efficient delivery of siRNA to a heart transplant model by a novel cell penetrating peptide-dsRNA binding domain.
79. A novel intracellular peptide derived from g1/s cyclin d2 induces cell death.
80. Genomic DNA recombination with cell-penetrating peptide-tagged cre protein in mouse skeletal and cardiac muscle.
81. Modular analysis of hipposin, a histone-derived antimicrobial peptide consisting of membrane translocating and membrane permeabilizing fragments.
82. Cell-penetrating peptides mediated protein cross-membrane delivery and its use in bacterial vector vaccine.
83. TAT conjugated cationic noble metal nanoparticles for gene delivery to epidermal stem cells.
84. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
85. Prolongation of life in rats with malignant glioma by intranasal siRNA/drug codelivery to the brain with cell-penetrating peptide-modified micelles.
86. Cell penetrating peptides and cationic antibacterial peptides: two sides of the same coin.
87. LXXLL peptide converts transportan 10 to a potent inducer of apoptosis in breast cancer cells.
88. RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells.
89. Interaction between cell-penetrating peptides and acid-sensitive anionic oligopeptides as a model for the design of targeted drug carriers.
90. Exploration of the design principles of a cell-penetrating bicylic peptide scaffold.
91. Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA.
92. Effect of cell-penetrating peptide-conjugated estrogen-related receptor β on the development of mouse embryos cultured in vitro.
93. Anti-tumor efficacy of a therapeutic peptide based on thermo-responsive elastin-like polypeptide in combination with gemcitabine.
94. Quantitative evaluation of the cell penetrating properties of an iodinated Tyr-L-maurocalcine analog.
95. Amphipathic short helix-stabilized peptides with cell-membrane penetrating ability.
96. Probing label-free intracellular quantification of free peptide by MALDI-ToF mass spectrometry.
97. Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting.
98. Intracellular delivery of cell-penetrating peptide-transcriptional factor fusion protein and its role in selective osteogenesis.
99. Novel pH-sensitive charge-reversal cell penetrating peptide conjugated PEG-PLA micelles for docetaxel delivery: in vitro study.
100. Controlled apoptosis by a thermally toggled nanoscale amplifier of cellular uptake.
101. Basic cell penetrating peptides induce plasma membrane positive curvature, lipid domain separation and protein redistribution.
102. Design of novel cell penetrating peptides for the delivery of trehalose into mammalian cells.
103. Penetratin, a potentially powerful absorption enhancer for noninvasive intraocular drug delivery.
104. A novel cell-penetrating peptide derived from WT1 enhances p53 activity, induces cell senescence and displays antimelanoma activity in xeno- and syngeneic systems.
105. Identification of BP16 as a non-toxic cell-penetrating peptide with highly efficient drug delivery properties.
106. Rational design of a series of novel amphipathic cell-penetrating peptides.
107. Cell division responsive peptides for optimized plasmid DNA delivery: the mitotic window of opportunity?
108. A cell-penetrating peptide based on the interaction between c-Src and connexin43 reverses glioma stem cell phenotype.
109. The acceleration of boron neutron capture therapy using multi-linked mercaptoundecahydrododecaborate (BSH) fused cell-penetrating peptide.
110. Anti-tumoral effect of the mitochondrial target domain of Noxa delivered by an engineered Salmonella typhimurium.
111. Matrix stiffness affects endocytic uptake of MK2-inhibitor peptides.
112. Internalization routes of cell-penetrating melanoma antigen peptides into human dendritic cells.
113. Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells.
114. Nucleic acid delivery by cell penetrating peptides derived from dengue virus capsid protein: design and mechanism of action.
115. Cell penetration properties of a highly efficient mini maurocalcine Peptide.
116. Relationships between Cargo, Cell Penetrating Peptides and Cell Type for Uptake of Non-Covalent Complexes into Live Cells.
117. The stoichiometry of peptide-heparan sulfate binding as a determinant of uptake efficiency of cell-penetrating peptides.
118. Dual-acting stapled peptides target both HIV-1 entry and assembly.
119. On the cellular uptake and membrane effect of the multifunctional peptide, TatLK15.
120. Effect of Ala replacement with Aib in amphipathic cell-penetrating peptide on oligonucleotide delivery into cells.
121. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth.
122. Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo.
123. Cell penetrating peptide conjugated polymeric micelles as a high performance versatile nonviral gene carrier.
124. One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats.
125. Fusogenic-oligoarginine peptide-mediated delivery of siRNAs targeting the CIP2A oncogene into oral cancer cells.
126. A novel application of indolicidin for gene delivery.
127. p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation.
128. Cellular uptake on N- and C-termini conjugated FITC of Rath cell penetrating peptides and its consequences for gene-expression profiling in U-937 human macrophages and HeLa cervical cancer cells.
129. Cytoplasm-responsive nanocarriers conjugated with a functional cell-penetrating peptide for systemic siRNA delivery.
130. A pH-responsive α-helical cell penetrating peptide-mediated liposomal delivery system.
131. Dual-mode enhancement of metallothionein protein with cell transduction and retention peptide fusion.
132. The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption.
133. The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration.
134. Heat shock protein-mediated cell penetration and cytosolic delivery of macromolecules by a telomerase-derived peptide vaccine.
135. RNase non-sensitive and endocytosis independent siRNA delivery system: delivery of siRNA into tumor cells and high efficiency induction of apoptosis.
136. Novel application of polioviral capsid: development of a potent and prolonged oral calcitonin using polioviral binding ligand and Tat peptide.
137. Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment.
138. PSA-responsive and PSMA-mediated multifunctional liposomes for targeted therapy of prostate cancer.
139. Lipid nanocapsule functionalization by lipopeptides derived from human papillomavirus type-16 capsid for nucleic acid delivery into cancer cells.
140. p28, a first in class peptide inhibitor of cop1 binding to p53.
141. Evaluation of diverse peptidyl motifs for cellular delivery of semiconductor quantum dots.
142. Stearylated antimicrobial peptide [D]-K6L9 with cell penetrating property for efficient gene transfer.
143. Kinetic uptake profiles of cell penetrating peptides in lymphocytes and monocytes.
144. Enhanced brain distribution and pharmacodynamics of rivastigmine by liposomes following intranasal administration.
145. Cell surface clustering of heparan sulfate proteoglycans by amphipathic cell-penetrating peptides does not contribute to uptake.
146. Glioma therapy using tumor homing and penetrating peptide-functionalized PEG-PLA nanoparticles loaded with paclitaxel.
147. Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo.
148. Cell-penetrating bisubstrate-based protein kinase C inhibitors.
149. The NFL-TBS.40-63 anti-glioblastoma peptide enters selectively in glioma cells by endocytosis.
150. Intracellular translocation and differential accumulation of cell-penetrating peptides in bovine spermatozoa: evaluation of efficient delivery vectors that do not compromise human sperm motility.
151. Lipo-oligoarginine-based intracellular delivery.
152. Cell penetration and cell-selective drug delivery using α-helix peptides conjugated with gold nanoparticles.
153. Cell penetrating recombinant Foxp3 protein enhances Treg function and ameliorates arthritis.
154. Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin.
155. Polyarginine molecular weight determines transfection efficiency of calcium condensed complexes.
156. The potent antimicrobial properties of cell penetrating peptide-conjugated silver nanoparticles with excellent selectivity for gram-positive bacteria over erythrocytes.
157. Direct translocation of cell-penetrating peptides in liposomes: a combined mass spectrometry quantification and fluorescence detection study.
158. A protein transduction domain with cell uptake and selectivity profiles that are controlled by multivalency effects.
159. Folic acid-tethered Pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: conformational characterization and in vitro cellular uptake evaluation.
160. Mechanistic studies of intracellular delivery of proteins by cell-penetrating peptides in cyanobacteria.
161. Peptide-mediated intracellular delivery of miRNA-29b for osteogenic stem cell differentiation.
162. A novel cell-penetrating peptide derived from human eosinophil cationic protein.
163. A cell-penetrating peptide suppresses the hypoxia inducible factor-1 function by binding to the helix-loop-helix domain of the aryl hydrocarbon receptor nuclear translocator.
164. Different roles of cell surface and exogenous glycosaminoglycans in controlling gene delivery by arginine-rich peptides with varied distribution of arginines.
165. Western blot evaluation of siRNA delivery by pH-responsive peptides.
166. Novel cell penetrating peptides with multiple motifs composed of RGD and its analogs.
167. Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model.
168. Photostable fluorescent organic dots with aggregation-induced emission (AIE dots) for noninvasive long-term cell tracing.
169. New generation of efficient peptide-based vectors, NickFects, for the delivery of nucleic acids.
170. Intranasal delivery of cell-penetrating anti-NF-κB peptides (Tat-NBD) alleviates infection-sensitized hypoxic-ischemic brain injury.
171. Peptide-based glioma-targeted drug delivery vector gHoPe2.
172. Activatable cell penetrating peptide-conjugated nanoparticles with enhanced permeability for site-specific targeting delivery of anticancer drug.
173. Two functional motifs define the interaction, internalization and toxicity of the cell-penetrating antifungal peptide PAF26 on fungal cells.
174. The non-peptidic part determines the internalization mechanism and intracellular trafficking of peptide amphiphiles.
175. Evaluating the use of Apo-neocarzinostatin as a cell penetrating protein.
176. Peptide nucleic acids inhibit growth of Brucella suis in pure culture and in infected murine macrophages.
177. Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs.
178. The modification of Tapasin enhances cytotoxic T lymphocyte activity of intracellularly delivered CTL epitopes via cytoplasmic transduction peptide.
179. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model.
180. A new strategy for intracellular delivery of enzyme using mesoporous silica nanoparticles: superoxide dismutase.
181. Penetratin-mediated delivery enhances the antitumor activity of the cationic antimicrobial peptide Magainin II.
182. A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection.
183. Self-assembled BolA-like amphiphilic peptides as viral-mimetic gene vectors for cancer cell targeted gene delivery.
184. Synergy between cell-penetrating peptides and singlet oxygen generators leads to efficient photolysis of membranes.
185. Electrical potentiation of the membrane permeabilization by new peptides with anticancer properties.
186. Transduction of translationally controlled tumor protein employing TCTP-derived protein transduction domain.
187. Application of a proapoptotic peptide to intratumorally spreading cancer therapy.
188. PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors.
189. Investigation of follicular and non-follicular pathways for polyarginine and oleic acid-modified nanoparticles.
190. Pharmaceutical nanocarrier association with chondrocytes and cartilage explants: influence of surface modification and extracellular matrix depletion.
191. Small and stable phosphorylcholine zwitterionic quantum dots for weak nonspecific phagocytosis and effective Tat peptide functionalization.
192. CXCR4 stimulates macropinocytosis: implications for cellular uptake of arginine-rich cell-penetrating peptides and HIV.
193. Recombinant single-chain antibody with the Trojan peptide penetratin positioned in the linker region enables cargo transfer across the blood-brain barrier.
194. De novo design of a tumor-penetrating peptide.
195. Cell penetration peptides for enhanced entry of αB-crystallin into lens cells.
196. F3 peptide-functionalized PEG-PLA nanoparticles co-administrated with tLyp-1 peptide for anti-glioma drug delivery.
197. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells.
198. Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide.
199. Oligopeptides derived from autophosphorylation sites of EGF receptor suppress EGF-stimulated responses in human lung carcinoma A549 cells.
200. A new amphipathic, amino-acid-pairing (AAP) peptide as siRNA delivery carrier: physicochemical characterization and in vitro uptake.
201. Cell-penetrating peptides released from thermosensitive nanoparticles suppress pro-inflammatory cytokine response by specifically targeting inflamed cartilage explants.
202. Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1A1) expression by nanofiber-mediated siRNA gene silencing.
203. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery.
204. Penetratin-functionalized PEG-PLA nanoparticles for brain drug delivery.
205. Peptoid transporters: effects of cationic, amphipathic structure on their cellular uptake.
206. Direct cytosolic delivery of cargoes in vivo by a chimera consisting of D- and L-arginine residues.
207. Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems.
208. Crotamine: a novel cell-penetrating polypeptide nanocarrier with potential anti-cancer and biotechnological applications.
209. Effects of tryptophan content and backbone spacing on the uptake efficiency of cell-penetrating peptides.
210. Solid formulation of cell-penetrating peptide nanocomplexes with siRNA and their stability in simulated gastric conditions.
211. Self-assembled peptide (CADY-1) improved the clinical application of doxorubicin.
212. TAT-modified nanosilver for combating multidrug-resistant cancer.
213. Arginine-rich cell-penetrating peptides deliver gene into living human cells.
214. Enhanced targeted anticancer effects and inhibition of tumor metastasis by the TMTP1 compound peptide TMTP1-TAT-NBD.
215. Enhanced cell uptake of superparamagnetic iron oxide nanoparticles through direct chemisorption of FITC-Tat-PEG₆₀₀-b-poly(glycerol monoacrylate).
216. Highly efficient (R-X-R)-type carbamates as molecular transporters for cellular delivery.
217. Effect of the attachment of a penetration accelerating sequence and the influence of hydrophobicity on octaarginine-mediated intracellular delivery.
218. A protein transduction method using oligo-arginine (3R) for the delivery of transcription factors into cell nuclei.
219. Cell targeting peptide conjugation to siRNA polyplexes for effective gene silencing in cardiomyocytes.
220. Cellular translocation of a γ-AApeptide mimetic of Tat peptide.
221. The cell-penetrating peptide domain from human heparin-binding epidermal growth factor-like growth factor (HB-EGF) has anti-inflammatory activity in vitro and in vivo.
222. Recombinant peptide constructs for targeted cell penetrating peptide-mediated delivery.
223. Evaluation of the use of amphipathic peptide-based protein carrier for in vitro cancer research.
224. Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo.
225. Functionalization with C-terminal cysteine enhances transfection efficiency of cell-penetrating peptides through dimer formation.
226. Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.
227. Tuning the activity of mitochondria-penetrating peptides for delivery or disruption.
228. Control of pH responsive peptide self-association during endocytosis is required for effective gene transfer.
229. MAP-mediated nuclear delivery of a cargo protein.
230. Comparison of four different peptides to enhance accumulation of liposomes into the brain.
231. Enantiomer-specific bioactivities of peptidomimetic analogues of mastoparan and mitoparan: characterization of inverso mastoparan as a highly efficient cell penetrating peptide.
232. The natural cell-penetrating peptide crotamine targets tumor tissue in vivo and triggers a lethal calcium-dependent pathway in cultured cells.
233. Effective endogenous gene silencing mediated by pH responsive peptides proceeds via multiple pathways.
234. Tat(48-60) peptide amino acid sequence is not unique in its cell penetrating properties and cell-surface glycosaminoglycans inhibit its cellular uptake.
235. Screening of cell-penetrating peptides using mRNA display.
236. Structural rearrangements and chemical modifications in known cell penetrating peptide strongly enhance DNA delivery efficiency.
237. A cell-permeable fusion protein for the mineralization of human dental pulp stem cells.
238. Specific targeting of hypoxic tumor tissue with nitroimidazole-peptide conjugates.
239. Cellular uptake of Aib-containing amphipathic helix peptide.
240. Identification and characterization of a new family of cell-penetrating peptides: cyclic cell-penetrating peptides.
241. Preferential uptake of L- versus D-amino acid cell-penetrating peptides in a cell type-dependent manner.
242. Calcium condensed cell penetrating peptide complexes offer highly efficient, low toxicity gene silencing.
243. Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs.
244. The vimentin-tubulin binding site peptide (Vim-TBS.58-81) crosses the plasma membrane and enters the nuclei of human glioma cells.
245. Design and evaluation of variants of the protein transduction domain originated from translationally controlled tumor protein.
246. Design, synthesis and characterization of a new anionic cell-penetrating peptide: SAP(E).
247. Cell-Penetrating Penta-Peptides (CPP5s): Measurement of Cell Entry and Protein-Transduction Activity.
248. PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation.
249. CyLoP-1: a novel cysteine-rich cell-penetrating peptide for cytosolic delivery of cargoes.
250. An unusual cell penetrating peptide identified using a plasmid display-based functional selection platform.
251. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo.
252. Creation of a novel peptide with enhanced nuclear localization in prostate and pancreatic cancer cell lines.
253. Identification of a cardiac specific protein transduction domain by in vivo biopanning using a M13 phage peptide display library in mice.
254. Characterization of bioactive cell penetrating peptides from human cytochrome c: protein mimicry and the development of a novel apoptogenic agent.
255. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells.
256. Isolation of novel cell-penetrating peptides from a random peptide library using in vitro virus and their modifications.
257. Identification of a novel antitumor peptide based on the screening of an Ala-library derived from the LALF(32-51) region.
258. A cell-penetrating peptide derived from human lactoferrin with conformation-dependent uptake efficiency.
259. Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin.
260. Cell-surface accumulation of flock house virus-derived peptide leads to efficient internalization via macropinocytosis.
261. Synthesis and studies on cell-penetrating peptides.
262. Cytosolic targeting of macromolecules using a pH-dependent fusogenic peptide in combination with cationic liposomes.
263. Inhibition of HSP27 phosphorylation by a cell-permeant MAPKAP Kinase 2 inhibitor.
264. Conjugation with cationic cell-penetrating peptide increases pulmonary absorption of insulin.
265. Identification and characterization of a novel cell-penetrating peptide.
266. A novel cell-penetrating peptide sequence derived by structural minimization of a snake toxin exhibits preferential nucleolar localization.
267. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells.
268. Predicting cell-penetrating peptides.
269. Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein.
270. all-D proline-rich cell-penetrating peptides: a preliminary in vivo internalization study.
271. A novel cell-penetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids.
272. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides.
273. Creation of novel cell-penetrating peptides for intracellular drug delivery using systematic phage display technology originated from Tat transduction domain.
274. Temperature-, concentration- and cholesterol-dependent translocation of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells.
275. Characterization of a novel cell penetrating peptide derived from Bag-1 protein.
276. Structure-activity relationship study of the cell-penetrating peptide pVEC.
277. A cell-penetrating peptide derived from mammalian cell uptake protein of Mycobacterium tuberculosis.
278. Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide.
279. Mechanism of uptake of C105Y, a novel cell-penetrating peptide.
280. Characterisation of cell-penetrating peptide-mediated peptide delivery.
281. Comparative study of the skin penetration of protein transduction domains and a conjugated peptide.
282. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules.
283. Structure analysis of the protein transduction domain of human Period1 and its mutant analogs.
284. Interaction of primary amphipathic cell-penetrating peptides with phospholipid-supported monolayers.
285. A new peptide with membrane-permeable function derived from human circadian proteins.
286. Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat(47-57) through well-differentiated epithelial models.
287. New transport peptides broaden the horizon of applications for peptidic pharmaceuticals.
288. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells.
289. Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of gamma-zein.
290. The human antimicrobial peptide LL-37 transfers extracellular DNA plasmid to the nuclear compartment of mammalian cells via lipid rafts and proteoglycan-dependent endocytosis.
291. Uptake of analogs of penetratin, Tat(48-60) and oligoarginine in live cells.
292. PDX-1 protein containing its own antennapedia-like protein transduction domain can transduce pancreatic duct and islet cells.
293. Studies on the internalization mechanism of cationic cell-penetrating peptides.
294. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells.
295. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7.
296. Cell membrane translocation of the N-terminal (1-28) part of the prion protein.
297. Translocation of analogues of the antimicrobial peptides magainin and buforin across human cell membranes.
298. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake.
299. Cellular import mediated by nuclear localization signal Peptide sequences.
300. Targeting of nonkaryophilic cell-permeable peptides into the nuclei of intact cells by covalently attached nuclear localization signals.
301. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo.
302. Thrombospondin stimulates focal adhesion disassembly through Gi- and phosphoinositide 3-kinase-dependent ERK activation.
303. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo.
304. A peptide carrier for the delivery of biologically active proteins into mammalian cells.
305. Cellular internalization of a cargo complex with a novel peptide derived from the third helix of the islet-1 homeodomain. Comparison with the penetratin peptide.
306. Efficient intracellular delivery of GFP by homeodomains of Drosophila Fushi-tarazu and Engrailed proteins.
307. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors.
308. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization.
309. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters.
310. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery.
311. Evidence for an amphipathicity independent cellular uptake of amphipathic cell-penetrating peptides.
312. Deletion analogues of transportan.
313. Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens.
314. Structure-activity relationship of truncated and substituted analogues of the intracellular delivery vector Penetratin.
315. A highly membrane-active peptide in Flock House virus: implications for the mechanism of nodavirus infection.
316. Structural requirements for cellular uptake of alpha-helical amphipathic peptides.
317. Extensive cellular uptake into endothelial cells of an amphipathic beta-sheet forming peptide.
318. Conformations of primary amphipathic carrier peptides in membrane mimicking environments.
319. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus.
320. Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers.
321. Intercellular trafficking and protein delivery by a herpesvirus structural protein.
322. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent.
323. A novel DNA-peptide complex for efficient gene transfer and expression in mammalian cells.
324. Inhibition of nuclear translocation of transcription factor NF-kappa B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence.
325. Neurotrophic activity of the Antennapedia homeodomain depends on its specific DNA-binding properties.

1. WO 2011/020188 A1.
2. US20110107443.
3. US20110027300.
4. US20100004165.
5. US 7943581.
6. US 7879813B2.
7. US 7754678.
8. US 7192921.
9. US 7153931.
10. US 7112442.
11. US 7101844.
12. US 6881825.
13. US 6740524.
14. US 6593292.
15. US 2014/0140929 A1.
16. US 20100216716.
17. US 20100203611.
18. US 20100168034.
19. US 20100137187.
20. US 20090221508.
21. US 20090186802.
22. US 20090030178.
23. US 20060223752 A1.
24. US 20060035815 A1.
25. US 20040132970.
26. EP 2491952 A1.